WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , Scientific Journal Impact Factor (SJIF) , IFSIJ Measure of Journal Quality , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , Research Publication Rating and Indexing , Doi-Digital Online Identifier , ISSN National Centre , Zenodo Indexing , International CODEN Service, USA , 

ISSN 2457-0400

Impact Factor  :  7.675

WJAHR Citation

  All Since 2020
 Citation  105  60
 h-index  4  4
 i10-index  3  2

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased from  5.464 to 7.675 for Year 2026.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR September 2026 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: SEPTEMBER ISSUE PUBLISHED

    SEPTEMBER 2026 Issue has been successfully launched on1 SEPTEMBER 2026.

Best Article Awards

World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

EVALUATION OF SOME HEMOSTATIC ABNORMALITIES IN CHRONIC KIDNEY DISEASE PATIENTS PRE AND POST HEMODIALYSIS

*Safa Asaad Al-Saffar, Dr. Muna Abdulbasit Kashmoola

ABSTRACT

Background: Chronic kidney disease and hemodialysis associated with disturbance in hemostasis. Uremic toxins induced platelet dysfunction, coagulopathy, endothelial dysfunction and impaired fibrinolysis. Aim: To evaluate some hemostatic abnormalities in patients with chronic kidney disease before and after hemodialysis. Patients and methods: A case-control study, involving (50) patients with chronic kidney disease on regular hemodialysis admitted to Ibn-Sina Teaching Hospital in Mosul city between April to September 2025, and (30) healthy controls. The sample underwent hemostatic investigations (pre and post hemodialysis) including: prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer, factor VIII, and Von Willebrand factor. Results: The mean age was 50.96 years, including 66% male and 34% female, the M: F ratio is 1.9: 1. The mean of prothrombin time (after hemodialysis), activated partial thromboplastin time, fibrinogen, D-dimer, factor VIII and von Willebrand factor were significantly higher in patients with chronic kidney disease in comparison to control. The mean of prothrombin time, activated partial thromboplastin time, D-dimer, and factor VIII after hemodialysis were significantly higher than before hemodialysis with P-value of (0.000), (0.032), (0.040) and (0.002) respectively. There was statistically significant direct correlation between prothrombin time and glomerular filteration rate before dialysis (r= -283, p=0.046). There was negative statically significant correlation between activated partial thromboplastin time before dialysis with factor VIII (r=-0.502, p=0.000). Conclusions: the current study concluded that the hemostatic markers were further increased after hemodialysis, which increased risk of bleeding and thromboembolic events.

[Full Text Article] [Download Certificate]